缬沙坦剂量对心力衰竭患者心室-血管耦合指数的剂量依赖性

摘要/Abstract

摘要： 目的探究应用不同剂量缬沙坦对心力衰竭患者心室-血管耦合指数的影响。方法选取2020年1月—2022年8月于新疆生产建设兵团医院接受治疗的400例心力衰竭患者为研究对象,按照随机数表法将其区分为观察组（n=200,接受40 mg/d缬沙坦治疗）和对照组（n=200,接受80 mg/d缬沙坦治疗）,比较两组患者治疗效果差异、治疗前后心功能指标、心肌损伤指标以及不良反应发生率差异。结果观察组患者治疗显效数80例,有效数104例,总有效率较对照组患者略有降低,但差异无统计学意义（P>0.05）;治疗后两组患者的左室射血分数（LVEF）均较治疗前出现明显提高,左心室舒张末期内径（LVEDD）较治疗前出现明显降低,差异有统计学意义（P<0.05）,但组间比较差异无统计学意义（P>0.05）;治疗后两组患者心脏型脂肪酸结合蛋白（H-FABP）、N端脑钠肽前体（NT-proBNP）较治疗前出现明显降低,差异有统计学意义（P<0.05）,组间比较治疗后对照组患者NT-proBNP水平低于观察组,差异有统计学意义（P<0.05）;观察组不良反应总发生率明显低于对照组,差异有统计学意义（P<0.05）。结论缬沙坦在改善心力衰竭患者临床症状方面效果较好,可以改善患者心功能、缓解患者炎症状态,建议服用剂量设置为40 mg/d,增加剂量并不会显著提高治疗效果,但会明显提高患者的不良反应发生率。

关键词: 缬沙坦, 心力衰竭, 心室-血管耦合指数, 剂量计量性

Abstract: Objective To investigate the effect of different doses of valsartan on ventricular vascular coupling index in patients with heart failure. Methods 400 patients with heart failure who were treated in our hospital from January 2020 to August 2022 were selected as the research objects. They were divided into the observation group (n=200, receiving 40 mg/d valsartan) and the control group (n=200, receiving 80 mg/d valsartan) according to the random number table method. The difference of the treatment effect between the two groups was compared, and the difference of the cardiac function index, myocardial injury index and adverse reaction rate index between the two groups before and after treatment was compared. Results The number of patients in the observation group was 80, and the number of patients in the observation group was 104. The total effective rate of the observation group slightly lower than that of the control group, but the difference was not significant(P>0.05); After treatment, LVEF and LVEDD of the two groups were significantly higher and lower than before treatment(P<0.05), but there was no significant difference between the two groups after treatment(P>0.05); After treatment, the levels of H-FABP and NT proBNP in the two groups were significantly lower than those before treatment(P<0.05). After treatment, the levels of NT proBNP in the control group were lower than those in the observation group(P<0.05); The total incidence of adverse reactions in the observation group was significantly lower than in the control group (P<0.05). Conclusion Valsartan is effective in improving the clinical symptoms of patients with heart failure. It can improve the heart function and alleviate the inflammatory state of patients. It is suggested that the dosage should be set at 40 mg/d. Increasing the dosage will not significantly improve the therapeutic effect, but will significantly increase the adverse reactions rate.

Key words: Valsartan, heart failure, Ventricular vascular coupling index, Dosimetry

中图分类号:

R541.6

郭雪峰. 缬沙坦剂量对心力衰竭患者心室-血管耦合指数的剂量依赖性[J]. 中华养生保健, 2023, 41(10): 51-54.

GUO Xue-feng. Dose Dependence of Valsartan Dose on Ventricular Vascular Coupling Index in Patients with Heart Failure[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(10): 51-54.

参考文献

[1] 夏勇,张建卿,王少霞,等.沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察[J].首都医科大学学报,2020,41(1):113-118.
[2] 崔玲玲,胡慧秀,孙超.慢性心力衰竭管理临床实践指南的质量评价与内容分析[J].中国护理管理,2021,21(2):243-248.
[3] 赵荫涛,裴小鑫,胡铂,等,刘源.Ghrelin对多柔比星诱导大鼠心力衰竭和心肌损伤的保护作用及机制[J].实用医学杂志,2021,37(1):30-34.
[4] 钟庆华,洪雷,方胜先,等.大剂量缬沙坦对心力衰竭患者神经内分泌及心室重构的影响[J].中国药业,2015,24(11):24-25.
[5] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[6] 董静. 三维超声心动图评价冠心病心力衰竭病人左心功能及其与血清NT-proBNP、H-FABP水平的相关性分析[J].中西医结合心脑血管病杂志,2020,18(22):3837-3840.
[7] 高峰,肖雪,于策,等.益气通脉方对气虚血瘀型慢性心力衰竭患者心肌重塑、氧化应激及血管内皮功能的影响[J].微循环学杂志,2022,32(2):40-44.
[8] 唐超,蔡琳,郭璐,等.胱抑素C与多发性肌炎/皮肌炎合并心力衰竭关系的横断面研究[J].中西医结合心脑血管病杂志,2019,17(23):3740-3744.
[9] 刘姗姗,边素艳,王逸飞,等.老年心力衰竭住院患者基础病因及并发疾病分析[J].中华老年心脑血管病杂志,2022,24(4):359-362.
[10] SEFEROVIĆ P M, VARDAS P, JANKOWSKA E A, et al.National Heart Failure Societies of the ESC member countries (see Appendix). The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019[J]. Eur J Heart Fail,2021,23(6):906-914.
[11] 张生长,黄伟剑.托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析[J].中国药物警戒,2019,16(8):467-472.
[12] 王鑫铭,杨春兰,董逸翔,等.类风湿关节炎患者血管紧张素Ⅱ水平与临床炎症指标相关性研究及ARBs类药物的治疗作用[J].中国药理学通报,2022,38(3):394-403.
[13] 张磊,丁辉.通心络胶囊联合沙库巴曲缬沙坦钠片治疗慢性心力衰竭的疗效及对患者心功能和炎症因子的影响[J].海南医学,2021,32(24):3162-3165.
[14] 黄程,邵云侠,吴艳,等.骨化三醇联合奥美沙坦酯治疗早期2型糖尿病肾病的效果及对肾病足细胞损伤的机制探讨[J].中国医药导报,2022,19(15):79-82.
[15] 柏静,孙宏丽,芦秋彤,等.可溶性生长刺激表达基因2联合N末端B型利钠肽原对沙库巴曲缬沙坦干预老年射血分数轻度减低心力衰竭患者的预后评估价值[J].中华老年多器官疾病杂志,2022,21(9):679-683.
[16] 詹雯雯,张海祥,刘园园,等.沙库巴曲缬沙坦治疗老年射血分数保留心力衰竭的效果及对炎性因子和生活质量的影响[J].临床误诊误治,2021,34(6):29-34.
[17] 毛银娟,杨礼,刘保民,等.心脏彩超评估高血压左心室肥厚伴左心衰竭患者心功能的临床价值及与NYHA分级的关系研究[J].现代生物医学进展,2019,19(23):4474-4478.
[18] 王寅,韩福生,江映天,等.不同初始剂量沙库巴曲缬沙坦治疗对慢性心力衰竭患者心室重构及心肌酶谱的影响[J].中国医院用药评价与分析,2021,21(6):667-670,677.